日本受试者中司巴丁多态性氧化的证据。
Evidence for polymorphic oxidation of sparteine in Japanese subjects.
作者信息
Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler H J
出版信息
Br J Clin Pharmacol. 1987 Apr;23(4):482-5. doi: 10.1111/j.1365-2125.1987.tb03080.x.
Abstract
The metabolism of sparteine which exhibits a genetic polymorphism in Caucasians was studied in 84 unrelated Japanese subjects. In contrast to a recent study where debrisoquine was used as a probe and no poor metabolizers could be observed in Japanese involving 100 subjects, two subjects had a urinary metabolic ratio of sparteine greater than 20 and thus were poor metabolizers of sparteine. The incidence of poor metabolizer phenotype of sparteine oxidation of 2% seems to be lower in Japanese as compared with various Caucasian populations where 5 to 10% are poor metabolizers of sparteine. However, this is not conclusive, because the 95% confidence interval of the observed frequency, 0.6 to 8%, covers the range reported in the literature for Caucasians.
摘要
在84名无亲缘关系的日本受试者中研究了在白种人中表现出遗传多态性的司巴丁代谢情况。与最近一项使用异喹胍作为探针的研究不同，在涉及100名受试者的日本人群中未观察到慢代谢者，但本研究中有两名受试者的司巴丁尿代谢率大于20，因此是司巴丁的慢代谢者。司巴丁氧化慢代谢者表型的发生率在日本人中为2%，与各种白种人群相比似乎较低，在白种人群中5%至10%是司巴丁的慢代谢者。然而，这并不具有决定性，因为观察到的频率的95%置信区间为0.6%至8%，涵盖了文献中报道的白种人的范围。
相似文献
1
Evidence for polymorphic oxidation of sparteine in Japanese subjects.日本受试者中司巴丁多态性氧化的证据。
Br J Clin Pharmacol. 1987 Apr;23(4):482-5. doi: 10.1111/j.1365-2125.1987.tb03080.x.
2
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.加纳人和德国人之间司巴丁氧化的种族间差异。
Eur J Clin Pharmacol. 1985;28(1):79-83. doi: 10.1007/BF00635712.
3
Sparteine oxidation polymorphism in Denmark.丹麦的鹰爪豆碱氧化多态性
Acta Pharmacol Toxicol (Copenh). 1985 Nov;57(5):357-60. doi: 10.1111/j.1600-0773.1985.tb00058.x.
4
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.日本人群中三种测试探针（美托洛尔、异喹胍和司巴丁）代谢率之间与遗传决定的氧化多态性的相关性。
Br J Clin Pharmacol. 1990 Jan;29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x.
5
Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.对西非人群中CYP2D6基因突变及其对酶功能影响的分析。
Pharmacogenetics. 1999 Dec;9(6):715-23.
6
The genetic polymorphism of sparteine metabolism.司巴丁代谢的基因多态性
Xenobiotica. 1986 May;16(5):465-81. doi: 10.3109/00498258609050252.
7
Comparative pharmacogenetics of sparteine and debrisoquine.鹰爪豆碱和异喹胍的比较药物遗传学
Clin Pharmacol Ther. 1983 Mar;33(3):394-9. doi: 10.1038/clpt.1983.51.
8
[Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease].
Rinsho Shinkeigaku. 1993 Mar;33(3):261-5.
9
[Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia].
Bratisl Lek Listy. 1997 Feb;98(2):86-90.
10
Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations.对日本人群中司巴丁氧化情况的进一步分析以及与不同种族人群中观察到的数据进行比较。
Xenobiotica. 1988 Sep;18(9):1077-84. doi: 10.3109/00498258809042230.
引用本文的文献
1
The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.阿立哌唑的临床药代动力学与 CYP2D6 遗传多态性的关系：帕罗西汀或氟伏沙明合用对 CYP 酶抑制的影响。
Eur J Clin Pharmacol. 2012 Jan;68(1):29-37. doi: 10.1007/s00228-011-1094-4. Epub 2011 Jul 8.
2
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.阿片类镇痛药临床反应的遗传预测因素：临床应用及未来展望。
Clin Pharmacokinet. 2004;43(14):983-1013. doi: 10.2165/00003088-200443140-00003.
3
Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.药物代谢酶的基因多态性：日本人CYP2D6和CYP2A6基因中的新突变
Pharm Res. 1998 Apr;15(4):517-24. doi: 10.1023/a:1011913407147.
4
The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.阿普林定的代谢与司巴丁/异喹胍多态性的关系。
Br J Clin Pharmacol. 1993 Apr;35(4):426-30. doi: 10.1111/j.1365-2125.1993.tb04161.x.
5
Genetically determined sparteine oxidation polymorphism in a Polish population.
Eur J Clin Pharmacol. 1994;46(5):481-3. doi: 10.1007/BF00191917.
6
N-acetylation polymorphism of dapsone in a Japanese population.日本人群中氨苯砜的N-乙酰化多态性
Br J Clin Pharmacol. 1988 Apr;25(4):487-94. doi: 10.1111/j.1365-2125.1988.tb03333.x.
7
N-acetylation phenotyping with dapsone in a mainland Chinese population.中国大陆人群中使用氨苯砜的N-乙酰化表型分析。
Br J Clin Pharmacol. 1988 Jan;25(1):81-7. doi: 10.1111/j.1365-2125.1988.tb03285.x.
8
Metoprolol oxidation in a Japanese population: evidence for only one poor metaboliser among 262 subjects.日本人群中的美托洛尔氧化：262名受试者中仅1名慢代谢者的证据。
Br J Clin Pharmacol. 1988 Dec;26(6):807-8. doi: 10.1111/j.1365-2125.1988.tb05325.x.
9
Apparent mendelian recessive inheritance of sparteine metabolism in an extended Japanese family.
Eur J Clin Pharmacol. 1988;34(6):661-2. doi: 10.1007/BF00615236.
10
Polymorphic sparteine metabolism and amyotrophic lateral sclerosis.多态性司巴丁代谢与肌萎缩侧索硬化症
J Neurol. 1989 Dec;236(8):452-5. doi: 10.1007/BF00328505.
本文引用的文献
1
Genetical and geographic studies on isoniazid inactivation.关于异烟肼失活的遗传学和地理学研究。
Science. 1961 Nov 10;134(3489):1530-1. doi: 10.1126/science.134.3489.1530.
2
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
3
Deficient metabolism of debrisoquine and sparteine.异喹胍和鹰爪豆碱代谢缺陷。
Clin Pharmacol Ther. 1980 Apr;27(4):547-9. doi: 10.1038/clpt.1980.77.
4
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.鹰爪豆碱和异喹胍的多态性氧化：相关药物遗传学实体。
Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.
5
Sparteine metabolism in Canadian Caucasians.
Clin Pharmacol Ther. 1982 Jan;31(1):23-9. doi: 10.1038/clpt.1982.4.
6
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷：药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
7
Polymorphic drug oxidation in humans.人类的多态性药物氧化
Fed Proc. 1984 May 15;43(8):2298-302.
8
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.运用分析双峰分布的新方法对人司巴丁和异喹胍代谢的遗传控制。
J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321.
9
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.日本人群与白种人群之间在异喹胍和甲妥英羟基化遗传多态性上的种族差异。
Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194.
10
Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.美芬妥因p(4')-羟化作用的基因多态性：东方人与高加索人的差异。
Br J Clin Pharmacol. 1985 Apr;19(4):483-7. doi: 10.1111/j.1365-2125.1985.tb02673.x.
Zotero 插件